SHENZHEN, China – 27April026 – Shenzhen MagicRNA Biotechnology Co., Ltd. (MagicRNA), a clinical-stage biotechnology company pioneering next-generation mRNA and lipid nanoparticle (LNP) delivery technologies, today announced that its lead program, “in Vivo CD19 CAR T-cell Therapy Induces Tissue B-cell Depletion in Systemic Lupus Erythematosus,” has been selected for an oral presentation at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

This selection underscores MagicRNA’s clinical leadership in engineered cell-targeted delivery and highlights the expanding global impact of innovative biotechnology in the cell and gene therapy (CGT) sector.

Delivering on the Promise of Scalable in Vivo Therapies

The 2026 ASGCT Annual Meeting marks a pivotal transition for the CGT industry: the shift from bespoke, proof-of-concept interventions to scalable, accessible treatments for broadly prevalent conditions. MagicRNA’s upcoming presentation places the company at the forefront of this evolution, directly addressing the industry's urgent need to overcome extrahepatic delivery bottlenecks using non-viral vectors.

Scheduled for May 13, 2026, the oral presentation will showcase breakthrough clinical data for MagicRNA's lead pipeline asset, HN2301, in the treatment of systemic lupus erythematosus (SLE). The therapy leverages the company's proprietary Engineered Cell-Targeted Delivery Platform (EnC-LNP).

As the first cell-targeted LNP therapeutic to enter human clinical trials globally, HN2301 has successfully achieved in vivo CAR-T reprogramming and robust B-cell depletion. Demonstrating a favorable safety profile alongside promising preliminary efficacy, this non-viral approach bypasses the complex manufacturing and infrastructure limitations of traditional ex vivo cell therapies. These outcomes strongly align with ASGCT's 2026 mandate to advance scalable, outpatient-friendly modalities for highly prevalent autoimmune diseases.

About MagicRNA

Founded in 2021, MagicRNA is a clinical-stage biotechnology company focused on advancing next-generation mRNA and LNP delivery technologies. Its proprietary Engineered Cell-Targeted LNP (EnC-LNP) platform enables precise mRNA delivery to extrahepatic non-antigen-presenting cells (non-APCs), successfully overcoming a key limitation of conventional LNPs. Powered by this platform, MagicRNA’s in vivo CAR-T program has entered the clinical stage as the world’s first cell-targeted LNP drug to be evaluated in humans. The foundational breakthrough clinical results supporting this approach have been published in the New England Journal of Medicine (NEJM).

"Being selected for an oral presentation at ASGCT is a profound validation of our technology platform and its alignment with the future of genomic medicine," said Dr. Gavin Zha, Founder of MagicRNA. "The industry is actively seeking robust in vivo delivery solutions to make cell therapies accessible for broader patient populations. We will continue to deepen our expertise in nucleic acid delivery, accelerate the clinical translation of our in vivo cell reprogramming therapies, and remain steadfast in our commitment to benefiting patients globally."

Session Information Summary:

•  Abstract ID: 224

•  Presentation Title: In Vivo CD19 CAR T-cell Therapy Induces Tissue B-cell Depletion in Systemic Lupus Erythematosus

•  Session: Clinical Trials: In Vivo Gene Transfer and Gene Editing Therapies

•  Date & Time: May 13, 2026 |16:30 -16:45 (ET)

•  Location: MCEC Room 210ABC (Level 2)